LENZ Therapeutics
LENZ
63 hedge funds and large institutions have $91.2M invested in LENZ Therapeutics in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 14 closing their positions.
25% more call options, than puts
Call options by funds: $507K | Put options by funds: $406K
13% more capital invested
Capital invested by funds: $80.7M → $91.2M (+$10.5M)
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
0% more funds holding
Funds holding: 63 → 63 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
0.17% less ownership
Funds ownership: 7.44% → 7.27% (-0.17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$2.94M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.43M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$1.21M |
| 4 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
+$750K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$464K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.35M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.21M |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$1.1M |
| 4 |
Renaissance Technologies
New York
|
-$903K |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$825K |
LENZ Hedge Fund Activity: Q3 2022 in Review
63 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q3 2022, worth a combined $91.2M — up 13% from $80.7M a quarter earlier.
Fund positioning in LENZ was balanced in Q3 2022: 14 funds opened new positions, 14 closed out, 17 added to existing stakes and 16 trimmed.
The largest buyer was Avidity Partners Management, adding an estimated $2.94M. The largest seller was Morgan Stanley, cutting an estimated $2.35M.
- 63 institutional investors held LENZ Therapeutics (LENZ) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $91.2M of LENZ Therapeutics stock for Q3 2022, up 13% quarter-over-quarter.
- 14 funds opened new LENZ Therapeutics positions in Q3 2022 and 14 closed out, a net change of 0 holders.
- The largest LENZ Therapeutics buyer in Q3 2022 was Avidity Partners Management, an estimated $2.94M added.
- The largest LENZ Therapeutics seller in Q3 2022 was Morgan Stanley, an estimated $2.35M sold.
Based on aggregated 13F filings for Q3 2022.